Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma

Diana M Carvalho1, Peter J Richardson2, Nagore Olaciregui3, Reda Stankunaite4, Cinzia Lavarno3, Valeria Molinari1, Elizabeth A Corley5, Daniel Smith2, Ruth Ruddle8, Adam Donovan6, Akos Pal6, Florence I Raynaud6, Sara Temelso1, Alan Mackay1, John P Overington7, Anne Phelan2, David Sheppard2, Andrew Mackinnon5,8, Bassel Zebian9, Safa Al-Sarraj10, Ashirwad Merve11, Jeremy Pryce12, Jacques Grill13, Michael Hubank4, Ofelia Cruz14, Andres Morales La Madrid14, Sabine Mueller15,16, Angel M Carcaboso3, Fernando Carceller5,17# and Chris Jones18#

1Division of Molecular Pathology, Institute of Cancer Research, London, UK; 2Benevolent AI, London, UK; 3Laboratory of Molecular Oncology, Hospital Sant Joan de Déu, Barcelona, Spain; 4Molecular Diagnostics, Royal Marsden Hospital NHS Trust, Sutton, UK; 5Children & Young People’s Unit, Royal Marsden Hospital NHS Trust, Sutton, UK; 6Division of Cancer Therapeutics, Institute of Cancer Research, London, UK; 7Medicines Discovery Catapult, Alderley Edge, UK; 8Atkinson Morley Regional Neuroscience Centre, St George’s Hospital NHS Trust, London, UK; 9Department of Neurosurgery, Kings College Hospital NHS Trust, London, UK; 10Department of Clinical Neuropathology, Kings College Hospital NHS Trust, London, UK; 11Institute of Neurology, University College London Hospitals, London, UK; 12South West London Pathology, St George’s Hospital NHS Trust, London, UK; 13Department of Pediatric and Adolescent Oncology and INSERM Unit U891, Team “Genomics and Oncogenesis of Pediatric Brain Tumors”, Gustave Roussy and University Paris-Saclay, Villejuif, France; 14Paediatric Oncology, Neuro-Oncology Unit, Hospital Sant Joan de Déu, Barcelona, Spain; 15University Children’s Hospital, Zurich, Switzerland; 16University of California, San Francisco; 17Division of Clinical Studies, The Institute of Cancer Research, London, UK
Correspondence to:

Chris Jones, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK, chris.jones@icr.ac.uk, +44 (0)20 8722 4416

Fernando Carceller, Children & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton SM2 5PT, UK. fernando.carceller@icr.ac.uk, +44 (0)20 8722 4176

Keywords: AI, ACVR1, ALK2, vandetanib, everolimus, DIPG

Running title: Vandetanib and everolimus in ACVR1-mutant DIPG

Conflict of interest: PJR, and AP are employees of BenevolentAI
ABSTRACT

Somatic mutations in ACVR1 are found in a quarter of children with diffuse intrinsic pontine glioma (DIPG), however there are no ACVR1 inhibitors licensed for the disease. Using an Artificial Intelligence-based platform to search for approved compounds for ACVR1-mutant DIPG, the combination of vandetanib and everolimus was identified as a possible therapeutic approach. Vandetanib, an inhibitor of VEGFR/RET/EGFR, was found to target ACVR1 (Kd=150nM) and reduce DIPG cell viability in vitro, but has limited ability to cross the blood-brain-barrier. In addition to mTOR, everolimus inhibits ABCG2 (BCRP) and ABCB1 (P-gp) transporters, and was synergistic in DIPG cells when combined with vandetanib in vitro. This combination is well-tolerated in vivo, and significantly extended survival and reduced tumor burden in an orthotopic ACVR1-mutant patient-derived DIPG xenograft model. Four patients with ACVR1-mutant DIPG were treated with vandetanib plus mTOR inhibitor, informing the dosing and toxicity profile of this combination for future clinical studies.

STATEMENT OF SIGNIFICANCE

25% patients with the incurable brainstem tumour DIPG harbour somatic activating mutations in ACVR1, however there are no approved drugs targeting the receptor. Using Artificial Intelligence, we identify and validate the novel combination of vandetanib and everolimus in these children based upon both signalling and pharmacokinetic synergies, experimentally and clinically.
INTRODUCTION

Diffuse intrinsic pontine glioma (DIPG) is an incurable infiltrating glioma of the brainstem in children, with a median overall survival (OS) of 9–12 months (1-3). Radiotherapy is the only treatment paradigm that provides a therapeutic response although >90% children suffer a relapse and die from their disease within 2 years (1,3,4). This tumour type comprises approximately 10% of all paediatric brain tumours and outcomes remain poor, partly due to its unique biology as evidenced by the high prevalence (>80%) of lysine-to-methionine substitutions at position 27 (K27M) in the H3F3A, HIST1H3B, and HIST1H3C genes (5,6).

Mutations commonly associated with the H3.1K27M substitutions include those in the ACVR1 gene which is mutated in approximately 25% of all DIPG tumours. These mutations have been reported at a younger age of diagnosis and with a slightly prolonged OS in children with DIPG (7-10). At least nine such mutations have been recognised predominantly within or close to the tyrosine kinase domain of the receptor (11). These mutations result in an abnormal sensitivity to Activin A (12) and/or constitutive receptor activation even in the absence of activating ligands (13). We (12) and others (14) have recently demonstrated that ACVR1 inhibition by selective inhibitors inhibits the growth of orthotopic tumours bearing ACVR1 mutations. However, the clinical development of these and related compounds still remains to be undertaken before clinical trials can take place.

One way of accelerating the discovery of treatments of DIPG is the repurposing of currently approved drugs, singly or in combination. This concept has to-date focussed on unbiased screens of such approved compound libraries, and by doing so has identified important novel therapeutic options for clinical use, particularly the HDAC inhibitor panobinostat alone (15) or combined with the proteasome inhibitor marizomib (16). Other candidates such as the IGF1R (and other receptor tyrosine kinase, RTK) inhibitor BMS-754807 (17), the FGFR inhibitor ponatinib (18), along with disulfiram, as well as MDM2 and Bcl2 inhibitors (19) are also being explored. An alternative approach which enables the exploitation of the enormous amount of
scientific data available to researchers is to use artificial intelligence (AI) methods, which are only recently being harnessed for cancer drug discovery (20).

To facilitate such an AI-augmented approach for ACVR1-mutant DIPG, BenevolentAI used an internally developed biomedical knowledge graph. This graph contains in excess of a billion provenanced relationship edges linking disease, biological mechanisms and drug targets which are derived automatically from both structured and unstructured data. As example of the power of such an approach, this platform was queried in early 2020 in the search for an approved drug which could be used in the treatment of the COVID-19 pandemic. In early 2020 this resulted in the identification of the anti-inflammatory drug baricitinib as a potential therapeutic capable of reducing viral infectivity and the associated over exuberant inflammation seen in this disease (21-24). As a result, baricitinib has been used in multiple investigator-led clinical trials and in two major randomised clinical trials, one recently published (25).

For ACVR1-mutant DIPG we used this knowledge graph to identify compounds that could be used to inhibit ACVR1, with a particular focus on the likely ability to identify compounds that would cross the blood-brain barrier. In the present study, we demonstrate that two approved drugs, used in combination (vandetanib and everolimus) worked synergistically \textit{in vitro} and \textit{in vivo} to inhibit the growth of tumours bearing ACVR1 mutations, and report the early clinical experience in children with ACVR1-mutant DIPG. Although careful management of side-effects and prior treatment will be essential, such an approach may form the basis for future formal clinical trials of the combination in patients with this genotype.
RESULTS

*AI-based identification of approved therapeutics*

The BenevolentAI knowledge graph contains over 40 million documents and over 1 billion relationship edges. It contains diseases, biological tissues, mechanisms and pathways, gene ontology processes, genes and proteins as well as drugs, biologics and small molecules (26). In order to find approved drugs with activity against ACVR1 that could be rapidly explored in the clinical context, we searched the knowledge graph for compounds which may have inhibitory effects on the ALK2 protein. Inherent within this approach was the necessity to find drugs with known central nervous system (CNS) penetration. 856 compounds which inhibit ALK2 enzyme activity were identified and then prioritised according to potency (IC$_{50}$) and whether they had been approved by the regulators for medicinal use. No approved drugs were identified which would be predicted to penetrate the CNS at sufficient concentrations to inhibit ALK2 using therapeutic doses. The four most promising compounds in terms of nM ALK2 efficacy (vandetanib, dasatinib, crizotinib and nintedanib) had insufficient brain exposures as a result of being substrates of the blood brain barrier efflux transporters ABCB1 (P-gp) and/or ABCG2 (BCRP) (27,28).

We therefore queried whether a combination of a putative ACVR1 inhibitor and another drug known to interfere with the drug transporter mediated efflux could be found which had been previously shown to be safe in humans. In addition, compounds were assessed for possible feedback mechanisms which themselves could be blunted by the combination of inhibitors. The AI system output suggested combinations of vandetanib or dasatinib with mTOR / FKBP12 inhibitors such as everolimus or sirolimus. Since everolimus has the higher affinity for mTOR / FKBP12 and has already been approved for cancer treatment we selected it as the candidate mTOR / ABC transporter inhibitor. Both dasatinib and vandetanib are being used in clinical trial combinations with everolimus suggesting both combinations are already being considered in children and adults [NCT03352427, NCT01582191]. The sequence of the logic is shown in Figure 1.
**Validation of selected agents**

Dasatinib as a multi-kinase inhibitor had been previously suggested as an ACVR1 inhibitor (29), as had the ALK/MET inhibitor crizotinib (30). To the best of our knowledge, vandetanib, used clinically as a VEGFR/EGFR/RET inhibitor, had not. Publicly available KINOMEscan data (31) for vandetanib indicated a Kd for ACVR1 of 150nM (in comparison to EGFR of 4.8nM, RET of 14.0nM, and VGFR1 of 260nM) (Figure 2A). We next used biochemical assays to assess the ability of these compounds to inhibit the ALK2 protein, along with the most common mutations found in DIPG, in comparison to the tool ACVR1 inhibitor LDN-214117. There were no significant differences between IC50 values against wild-type or mutant ALK2 (including the constitutively activating mutation Q207E) for any of the agents tested (Figure 2B). Vandetanib, however, was 5-6-fold more potent against ACVR1 than either dasatinib or crizotinib (IC50 466 nM vs 2894 nM and 2334 nM, respectively, p<0.0001, ANOVA), albeit also an average of ~9-fold less potent than LDN-214117 (IC50 466 nM vs 51 nM, p<0.0001, ANOVA) (Supplementary Figure S1).

There was a small but significant enhanced difference in cell viability *in vitro* in ACVR1-mutant compared to wild-type patient-derived DIPG cells treated with vandetanib (~2-fold, p=0.0272, t-test) (Supplementary Figure S2A), that was accompanied by a concentration-dependent inhibition of phosphorylated SMAD1/5/8, in addition to the expected effect on phosphorylated Akt (Ser473) at the highest dose in ACVR1-R206H HSJD-DIPG-007 cells (Supplementary Figure S2B). These effects were not observed with everolimus (Supplementary Figure S2C), though there was a reduction in ID1 (Supplementary Figure S2D). Notably, when the two drugs were combined, expression of both ID1 and the mTOR target phospho-S6 kinase was ablated when treated with even the lowest doses of vandetanib in the presence of 10µM everolimus (Figure 2C).
Next, everolimus was explored for its ability to inhibit key transporter pumps in an \textit{in vitro} Caco-2 permeability assay. Whilst vandetanib showed weak interactions with P-gp and BCRP, everolimus significantly decreased the B-A apparent permeabilities of control substrates with both transporters (p<0.0001, t-test for both BCRP and P-gp) (Figure 2D, 2E). The addition of vandetanib made no effect to either when tested in combination. In non-tumour-bearing mice \textit{in vivo}, treatment with 10µM everolimus increased the median brain concentration of vandetanib by 56% compared to vandetanib alone, though this failed to reach statistical significance due to one mouse failing to show an effect (p=0.0854, t-test) (Figure 2F).

\textbf{Efficacy of combined vandetanib and everolimus in ACVR1-mutant DIPG models}

Having validated the key tenets of the individual drugs, we next sought to explore the effects of combining them on patient-derived ACVR1-mutant DIPG cells. We used the BLISS independence model to assess the combination of vandetanib and everolimus in terms of cell viability in \textit{H3F3A K27M, ACVR1 R206H} mutant HSJD-DIPG-007 (Figure 3A, 3B, 3C), and \textit{HIST1H3B K27M, ACVR1 R258G} mutant HSJD-DIPG-018 (Figure 3D, 3E, 3F). In both models, profound effects were seen, especially at low doses of both drugs (Figure 3A, 3D). This was more formally evaluated by calculating the excess above BLISS scores for each pairwise combination, identifying likely synergistic areas within the combinatorial matrix (Figure 3B, E). A summary synergy score was calculated as the average excess response due to drug interactions above expectation, with the resulting value of 17.25 indicating a high degree of formal synergy in HSJD-DIPG-007 (Figure 3C), and a more restricted synergistic interaction at lower doses of vandetanib in HSJD-DIPG-018 (overall score 4.08, peak value 7.72 (Figure 3F).

Prior to assessing the efficacy of the combination \textit{in vivo}, we ensured that combined vandetanib and everolimus was well tolerated in non-tumour-bearing mice. There was no reduction in body weight outside allowed parameters, and animals remained healthy during the 14-day course (Figure 4A). We used two distinct DIPG mouse models for testing the
combined treatment – a patient-derived xenograft (PDX) model of HSJD-DIPG-007 (12), and an allograft of cells derived from a Nestin-Tv-a; Trp53fl/fl; Hist1h3b_K27M, Acrv1_R206H genetically engineered mouse model (GEMM) (14), both implanted orthotopically. Mice were treated with either agent alone or in combination, with a separate pre-post-treatment arm to assess tumour burden (Figure 4B). After a four-week schedule of five days on, two days off treatment, combined vandetanib and everolimus was found to extend survival by two weeks in the HSJD-DIPG-007 PDX model compared to control (117 days combination versus 103 days, 14%, p=0.00072, median test), in contrast with either agent alone (log-rank p=0.0034 corrected for multiple testing) (Figure 4C). Similarly, the combination was found to significantly reduce tumour burden over the course of the four week treatment, as assessed by both ddPCR of the ACVR1_R206H mutation (ANOVA p=0.0197) (Figure 4D), and immunohistochemical staining of human nuclear antigen (ANOVA p=0.0017, both corrected for multiple testing) (Figure 4E and Supplementary Figure S3A). In the GEMM allografts (Supplementary Figure 3B), we observed an extension of median survival of 60 versus 38 days (58%, p=0.0375, median test), however this failed to reach formal statistical significance in survival analysis (log-rank p=0.200), with some unexpectedly longer-term survivors in the vehicle-treated arm (Figure 4F). Measuring tumour penetration of vandetanib when combined with everolimus in the different murine backgrounds used, we noted significantly higher levels (>15µM) in both normal brain and PDX in nude mice (Figure 4G), compared with the normal and GEMM allograft in NSG (10µM and <5µM, respectively) (Figure 4H), though still in excess of in vitro GI50 values.

Clinical experience in ACVR1-mutant DIPG patients

Four children with DIPG for whom ACVR1 mutations were confirmed in stereotactic tumour biopsy and/or peripheral blood were treated with vandetanib and an mTOR inhibitor. Three of them have annotated clinical details and treatment-related toxicities (Tables 1 and 2). A fourth case of DIPG received vandetanib and everolimus at relapse and was subsequently lost to follow-up.
Case #1. Seven year-old female diagnosed with DIPG in May 2019 under the South Thames Paediatric Neuro-Oncology Team (London, UK). She was enrolled in the BIOMEDE trial (NCT02233049) and underwent a biopsy, but failed screening because of elevated ALT (grade 3). Standard focal photon beam radiotherapy was administered off-trial. She then received three cycles of everolimus single agent on a compassionate use basis. Following identification of an ACVR1_G328V mutation (Figure 5A), vandetanib was added on a compassionate use basis in combination with everolimus up to a total of 7 cycles. The dosing schedule of this combination was carefully defined based on published evidence of vandetanib +/- dasatinib in DIPG (28,32) and a phase I trial of vandetanib/everolimus in adults with advanced/metastatic lung cancer (33,34): vandetanib 65 mg/m²/day and everolimus 4 mg/m²/day (34). The frequency and severity of toxicities were increased compared to everolimus single agent, but with acceptable tolerance to the point that the child was able to resume school part-time. The treatment was halted temporarily during cycles 1 and 5 due to transient clinical deterioration (increased facial droop, slurred speech and unsteadiness). On both occasions vandetanib/everolimus were restarted at the same doses, with stable MRI findings and following improvement after a short course of steroids. During cycle 6 she developed hypertension grade 3 unrelated to steroids. Vandetanib was interrupted temporarily until the blood pressure decreased to grade ≤1 on amlodipine. Everolimus was continued at the same dose. Other toxicities were transient and manageable and did not require dose reductions or interruptions (Table 2).

Sequential MRI scans showed slow but steady local tumour progression (Figure 5B). During cycle 7 the child developed increased slurred speech and ataxia and vandetanib/everolimus were permanently discontinued 11 months after diagnosis. No further systemic treatment or re-irradiation were administered. She then unexpectedly entered a “honeymoon period” of 8 months, during which the steroids could be stopped and her balance and activity levels went back to baseline. But eventually she developed again worsening slurred speech and ataxia.
MRI confirmed tumour progression locally and a metastatic deposit in the left lateral ventricle. The child passed away a month later with an overall survival of 20 months from initial diagnosis.

The family generously donated the patient’s brain tissue for post-mortem study (Figure 5C), whereby tumour cells were found to have infiltrated throughout the brainstem (Figure 5D). In addition to the HIST2H3C and ACVR1 mutations, which were found in all parts of the specimen, we observed the acquisition of a KRAS_G12A mutation, not found in the diagnostic biopsy, at high frequency in the main body of the tumour in the inferior left pons, and to a lesser extent in the right pons and superior specimens (Figure 5E). By contrast to a specimen taken from the cerebellum without tumour cell infiltration, these pontine regions were found to have substantially elevated MAPK signalling by quantitative capillary electrophoresis for phospho-ERK1/2_T202/Y204 (Figure 5F). This mutation is known to confer resistance to EGFR and other RTK inhibitors, such as vandetanib (35,36), and provides a rational explanation for eventual treatment failure in this case.

Case #2. Four year-old female diagnosed with DIPG in July 2019 at Hospital Sant Joan de Déu (Barcelona, Spain). A biopsy was performed as part of an institutional precision medicine program. She received standard focal photon beam radiotherapy. Soon after radiotherapy, she developed hydrocephalus and required a ventriculo-peritoneal shunt followed by bevacizumab due to suspected pseudoprogression. After two months of bevacizumab and having identified an ACVR1_G328E mutation, treatment was switched to vandetanib 65 mg/m²/day and sirolimus 3 mg/m²/day. After one cycle of vandetanib/sirolimus she developed increased ataxia, abnormal ocular movements and akathisia. A head CT scan showed an intratumoral haemorrhage and vandetanib/sirolimus were permanently discontinued. Neurological symptoms persisted despite steroids and she developed severe neuropsychological agitation and polyphagia as a result of prolonged use of steroids. Hence, one month after stopping vandetanib/sirolimus and following stabilization of the intratumoral...
haemorrhage, bevacizumab was restarted as steroid-sparing agent. The steroids could be weaned off and her restlessness resolved. After two additional months on bevacizumab, she experienced further clinical progression with stable MRI findings. She passed away a month later with an overall survival of 9 months from initial diagnosis.

Case #3. Four year-old female diagnosed with DIPG in January 2019 at Gustave Roussy (Paris, France). A biopsy was performed as part of the BIOMEDE trial (NCT002233049). She received standard focal photon beam radiotherapy together with dasatinib, showing clinical and radiological improvement at the end of radiotherapy. Eventually, she developed worsening symptoms as a result of necrotic degeneration of the tumour and bevacizumab was started due to suspected pseudoprogression. After 2 months on bevacizumab, steroids were stopped. In September 2019 (8 months after biopsy), she experienced tumour progression and hydrocephalus, requiring a ventriculo-peritoneal shunt. Based on a PIK3CA mutation dasatinib was switched to sirolimus and she underwent re-irradiation (18Gy in two weeks) in November 2019. Following a transient improvement, she developed further clinical deterioration and received two doses of bevacizumab, followed by tapering of the steroids, whilst continuing with sirolimus. With her tumour harbouring an ACVR1_G328E mutation, in April 2020 treatment was electively switched to combined vandetanib/everolimus (dosing as per Case #1). After one week on treatment, she developed hypertension grade 1 (no antihypertensives were started). She then progressively developed truncal hypotonia and, seventeen days after the start of vandetanib/everolimus, she was admitted with headaches and vomiting. A non-contrast head CT scan showed increased size of the brainstem with associated intratumoral haemorrhage. Despite mannitol and high-dose steroids, she deteriorated rapidly and passed away within 24 hours of admission.

Case #4. Four year-old male diagnosed with DIPG in January 2019, who was treated with cisplatin/temozolomide followed by standard focal radiotherapy, followed shortly after by
ONC201. He underwent a biopsy in April 2019 which identified \textit{HIST1H3B}\textsubscript{K27M} and \textit{ACVR1}\textsubscript{G328E} mutations. Between July-August 2019 he received three doses of Nivolumab. In September 2019, vandetanib/everolimus were started in Zurich (Switzerland). Treatment was discontinued within 10 weeks due to issues with compliance. His MRI post-vandetanib/everolimus showed significant inflammatory changes and cystic degeneration, which were challenging to interpret. The family subsequently pursued treatment overseas and the child was lost to follow up. He passed away 13 months after initial diagnosis.
DISCUSSION

With ACVR1 representing a promising therapeutic target for a significant proportion of DIPG patients, the need for translation of appropriate therapeutics is a high priority. In addition to specific approved inhibitors currently in development, repurposing of agents represents an attractive and more expedited option. A key criterion for drug repurposing is to identify agents active against the receptor at concentrations likely to be achieved within the tumour cells of DIPG patients. Here we have used a proprietary AI-based platform to identify a novel combination of the multi-RTK inhibitor vandetanib alongside the mTOR inhibitor everolimus, taking advantage of the abilities of the latter drug to inhibit both mTOR and the ABC efflux transporter pumps, which has previously limited clinical utility of the former compound against CNS tumours.

We validated the ability of vandetanib to directly inhibit both wild-type and mutant ACVR1 signalling, and in particular noted it be to more potent in this context than other purported kinase inhibitors such as dasatinib (29) and crizotinib (30). Although highly pleiotropic, we provide clear biochemical data that vandetanib inhibits both mutant and wild-type ACVR1, and a modest (~2-fold), though significantly increased potency in heterogeneous ACVR1-mutant patient-derived DIPG cells compared to wild-type. In these models, the combination was synergistic in vitro and extended survival in vivo. Although vandetanib does not have the potency against ACVR1 of other more selective agents (12), its ability to also inhibit the VEGFR pathway makes it additionally attractive in this context, given the reported ability of mutant ACVR1 to drive angiogenesis in DIPG (14). Similarly, the use of an mTOR-inhibitor in combination is strongly suggested in this genotype, given the significant co-segregation of genetic alterations targeting the PI3K pathway in ACVR1-mutant tumours (PIK3CA, PIK3R1, PTEN) (12,37). Importantly, we and others have shown combined targeting of ACVR1 and mTOR to be synergistic in vitro using both tool compounds and novel ACVR1 inhibitors in patient-derived DIPG models (38)(https://m4kpharma.com/recording-of-m4k-pharma-
Inhibition of the downstream SMAD target ID1 by vandetanib was also markedly more pronounced in the presence of everolimus, reflecting previous reports of the regulation of ID1 by mTOR (39), and presumably further underlying the synergistic effect we observed in vitro.

Vandetanib is an established inhibitor of VEGFR, EGFR and RET kinases, and is approved for the treatment of certain thyroid cancers. In common with many kinase inhibitors, vandetanib has been reported to have limited CNS penetration, as it is a substrate of ABC transporter pumps that limit crossing of small molecules across the blood-brain barrier (40). To overcome this, the use of everolimus to inhibit ABCB1 (Pgp) and ABCG2 (BCRP) has been shown to result in significantly increased vandetanib brain concentrations in mice (41). In adults, a patient with a KIF5B:RET fusion-positive non-small-cell lung cancer (NSCLC) and brain metastases showed a decrease in the intracranial disease burden upon treatment with vandetanib plus everolimus (33), as part of the phase I clinical trial in patients with advanced or metastatic cancer (NCT01582191). Here, fatigue, rash/acne, diarrhea, mucositis, hyperglycemia, hypertriglyceridemia, and hypercholesterolemia were the most common toxicities and 6/80 (7.5%) patients experienced DLTs (42). The maximum tolerated doses (MTD) and recommended phase 2 doses (RP2D) were defined as 300 mg OD for vandetanib and 10 mg OD for everolimus. Activity in terms of reduction of tumour volumes was noted to be significantly enhanced in patients with molecular alterations in the drug targets (RET, VEGFR, EGFR, PI3K/mTOR), supporting further development of the combination (42).

Given the urgent clinical need, we report the first use of this combination in children with DIPG treated in four expert paediatric neuro-oncology centres across Europe, in order to provide preliminary evidence of the dosing and toxicity profile of vandetanib/everolimus, which may serve as a reference for future clinical trials. Importantly, two of four patients treated with this combination developed an intratumoral haemorrhage (ITH) during the first cycle of vandetanib/mTOR-inhibitor. ITH may occur in 14-19% cases of DIPG (43) and tends to be
associated with underlying tumour progression. One of these patients had had a previous episode of pseudoprogression prior to vandetanib/sirolimus; and the other, two reported episodes of pseudoprogression plus one confirmed tumour progression prior to vandetanib/everolimus. Pseudoprogression rates in children with DIPG vary between 14-24% and diagnosis can only be made retrospectively (44,45). Hence, these episodes of pseudoprogression could have indeed represented genuine tumour progression. Notwithstanding, increased risk of bleeding is a known side effect of antiangiogenic drugs (46).

Of note, among 60 children with DIPG treated with vandetanib +/- dasatinib (28,32), no episodes of intratumoral haemorrhage were reported, but there were four episodes of gastrointestinal haemorrhage (three grade 3 and one grade 1-2), all of them in patients who had received both vandetanib/dasatinib. In our case series, both cases with ITH had received bevacizumab prior to vandetanib. Hence, an additive class-effect cannot be ruled out, as treatment with bevacizumab is itself a known risk factor for CNS haemorrhage (46,47), and so exclusion of patients with previous anti-angiogenic therapies may need to be considered; the increased CNS penetration of vandetanib when combined with everolimus could have also led to enhanced on-target antiangiogenic effects in this context.

The other side effects of vandetanib and everolimus observed in three clinically annotated cases were within the toxicity profile reported for this class of compounds (28,32,48). One child developed hypertension grade 3 attributable to vandetanib, which subsequently resolved with temporary discontinuation of the drug and initiation of antihypertensive medication. Survival outcomes for the reported cases were largely within those previously reported in historical cohorts of children with DIPG (43).

Vandetanib has been tested clinically in DIPG patients previously in two phase I trials, both as single agent (32), and combined with dasatinib (28). A total of 35 patients received vandetanib single-agent during and after radiotherapy (32). The maximum tolerated dose (MTD) was not reached, with only one dose-limiting toxicity (DLT) -diarrhoea grade 3- at the
highest dose level, and 145 mg/m$^2$/day was declared as the recommended phase II dose. Nevertheless, in the expansion phase two patients on high doses of dexamethasone concurrently experienced grade 4 hypertension and posterior reversible encephalopathy syndrome (PRES) during the first 10 days of treatment (one at 145 mg/m$^2$/day and the other at 110 mg/m$^2$/day). Additionally, other toxicities in patients treated with 110-145 mg/m$^2$/day included grade 3 hypertension, hypokalemia and photosensitivity (n=1 each); and grade 1-2 QTc prolongation (n=6). There were no objective responses. The 2-year OS was 21.4% (32). Unfortunately, no tumour tissue was available at diagnosis for molecular analysis, except for one case.

In the phase I trial of dasatinib/vandetanib 25 patients received the combination during and after radiotherapy. DLTs included grade 3 elevated amylase (n=2), elevated lipase, hypoalbuminemia, thrombocytopenia and diarrhoea (n=1 each) (28). The MTD of combined vandetanib and dasatinib was 65 mg/m$^2$/day for each drug. Outside of the DLT-evaluation period, the following relevant toxicities were reported: grade 4 anemia (n=2), neutropenia, thrombocytopenia, hypokalemia and infection (n=1 each); and grade 3 hypoalbuminemia (n=5), neutropenia, hypokalemia, diarrhoea and infection (n=4 each), gastrointestinal haemorrhage (n=3), hypertension and hypophosphatemia (n=2 each), prolonged QTc, proteinuria, fatigue, vomiting and anemia (n=1 each). All patients experienced progression with a 2-year OS of 9%.

Notably, amongst other RTKs, vandetanib inhibits EGFR. In our most extensively studied case, for which good quality of life was sustained for long periods prior to the child succumbing to the disease, a KRAS$\_G12A$ mutation was discovered at autopsy. This mutation has been shown to confer resistance to EGFR (49-51) and other RTK inhibitors including vandetanib (35,36) in non-small cell lung carcinoma. Although highlighting the likely acquisition of genetic alterations which allow treatment escape with any targeted inhibitor, these data are also strongly suggestive that vandetanib was reaching the tumour in sufficient quantities to exert
a growth inhibitory effect. In previous clinical trials with vandetanib in DIPG patients, PK studies found a CSF-to-plasma ratio for vandetanib of approximately 2% for two patients treated at 65 mg/m²/day² (28), thus suggesting a substantial improvement for our proposed combination.

Everolimus also represents an excellent backbone for combinatorial clinical studies in this disease given the wealth of safety data in DIPG patients (NCT02233049, NCT03352427, NCT0335579), and its demonstrated safety and tolerability in the BIOMEDE trial (NCT02233049) because of its safety and tolerability. The experience of everolimus in this age group may be of particular importance given the reservations expressed about the ability to provide clinical doses of the drug at sufficient concentrations to elicit significant inhibition of Pg-P (52). Notably, another recent study reported the use of everolimus to improve the CNS penetration of dasatinib in PDGFRA-driven high grade gliomas in children (53). Here, the authors found an increase in both plasma (11.2 ng/mL to 31.5 ng/mL) and CSF (0.44 ng/mL to 0.91 mg/mL) dasatinib levels in two patients after one week of dasatinib monotherapy and then after two cycles of dual therapy with dasatinib and everolimus (53), and pointed to adult phase I studies of higher doses of everolimus (up to 70 mg weekly) that were well-tolerated and resulted in mean peak levels of everolimus 10-fold higher than standard regimens (54).

In summary, vandetanib and everolimus is a feasible combination to trial for children with ACVR1-mutant DIPG, further mandating the inclusion of stereotactic and/or liquid biopsy approaches for molecular profiling to guide biology-driven stratified trials (55). Following treatment-induced changes by molecular profiling of sequential liquid biopsies and/or post-mortem specimens will help to improve our understanding of clonal evolution and mechanisms of resistance to such approaches. Going forward, a formal early phase clinical trial with standardized safety and efficacy monitoring will be essential in order to determine the clinical utility of such an approach for children with these tumours.
MATERIALS and METHODS

Identification of therapeutic combinations
The Benevolent Platform ingests and processes structured and unstructured data to create a proprietary knowledge graph comprising 1.2 billion relationships (gene-disease, gene-drug, drug-disease and gene-gene connections), 95% of which are extracted from unstructured data (i.e., scientific literature) and harmonizes biomedical data to build representations of disease biology. The graph is constantly being updated and curated in the light of new discoveries through machine reading. Inferences are drawn and relationships inferred between the entities in the graph through the use of proprietary AI algorithms including Rosalind (26), that combines relational inference via tensor factorization with graph-based data integration to predict disease genes and potential points of therapeutic intervention. The knowledge graph extracts data from heterogeneous sources, including literature evidence, differential expression, and clinical trial data, and consists of entities connected through relationships (such as ‘therapeutic relationship’ or ‘biological association’). In Rosalind, a tensor factorization model is trained on this heterogeneous knowledge graph to produce a ranked list of genes as targets for disease interventions. Rosalind uses a state-of-the-art scoring function that enables the modelling of asymmetric relationships between entities. For DIPG the graph was queried in the search for an approved drug capable of inhibiting one or more of the mutated putative drivers of this disease. In the light of the poor brain penetration of the identified drugs the graph was queried again in the search for a combination of drugs which had already been dosed in humans and which, through modulation of the drug efflux pumps, could increase the brain penetration.

Generation of wild-type and mutant ALK2 constructs:
All constructs (GST-6His-ALK2 variants) were optimized for expression in insect cells and were cloned into pOET1 using the flashBAC system (Oxford Expression Technologies). Sf9 cells were transfected with the ALK2 gene in pOET1 and flashBAC baculoviral genome. All
constructs were expressed at 300ml scale and proteins were purified using microscale affinity columns (glutathione or Ni-NTA Phynexus tips). Enzyme activity was measured by the ADP-Glo™ Kinase Assay (Promega).

**Caco-2 Permeability**

$P_{app}$ (apparent permeability) was determined in the Caco-2 human colon carcinoma cell line. Cells were maintained (DMEM with 10% fetal bovine serum, penicillin, and streptomycin) in a humidified atmosphere with 5%CO$_2$/95% air for 10 days. Cells were plated out onto a cell culture assembly plate (Millipore, UK), and monolayer confluency was checked using a TEER electrode prior to the assay. Media was washed off and replaced in the appropriate apical and basal wells with HBSS buffer (pH7.4). Bidirectional A-B and B-A apparent permeabilities of the test compounds Vandetanib and everolimus were determined in the presence of E3S (Estrone-3-sulfate, an ABCG2 (BCRP) substrate) or Indinavir (an ABCB1 (P-gp) substrate). LY335979 (P-gp inhibitor) and Ko134 (BCRP inhibitor) were used as positive controls. The Caco-2 plate was incubated for 2 h at 37 °C in humidified atmosphere with 5% CO$_2$, and Lucifer Yellow was used to confirm membrane integrity after the assay. Samples from the apical and basolateral chambers were analysed using reverse chromatography tandem mass spectrometry on a Waters TQ-S.

**Cell culture**

All patient-derived material for cell culture was collected under Research Ethics Committee approval from the originating centres. Cells were grown in stem cell media consisting of Dulbecco’s Modified Eagles Medium: Nutrient Mixture F12 (DMEM/F12), Neurobasal-A Medium, HEPES Buffer Solution 1 M, sodium pyruvate solution 100 nM, non-essential amino acids solution 10 mM, Glutamax-I Supplement and Antibiotic-Antimycotic solution (all Thermo Fisher, Loughborough, UK). The media was supplemented with B-27 Supplement Minus Vitamin A, (Thermo Fisher), 20 ng/ml Human-EGF, 20 ng/ml Human-FGF-basic-154, 20 ng/ml
Human-PDGF-AA, 20 ng/ml Human-PDGF-BB (all Shenandoah Biotech, Warwick, PA, USA) and 2 µg/ml Heparin Solution (0.2%, Stem Cell Technologies, Cambridge, UK). Cell authenticity was verified using short tandem repeat (STR) DNA fingerprinting.

**Compound efficacy assays**

Cells were plated at a density of 2000–4000 cells/well on laminin-coated 96-well plates in a minimum of triplicates. After three days of incubation, compounds were added to each well and incubated at 37 °C, in 5% CO₂, 95% humidity for eight days (192 h). Drugs were combined by adding one compound in rows and another in columns with serial dilutions resulting in a 6 x 9 dose matrix. Vandetanib and everolimus were purchased from Selleckchem. Cell viability was assessed by the CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI, USA). SynergyFinder ([https://synergyfinder.fimm.fi](https://synergyfinder.fimm.fi)) was used for interactive analysis and visualization of drug combination profiling data following the Bliss independence model (56).

**Western Blot analysis**

For treatment with Vandetanib and everolimus, cells were incubated in complete media with vehicle or increasing concentrations of drug (0.1, 1, 10 µM) and protein was collected at 4 and 8 h post-treatment. Mouse brain samples were manually homogenised in protein cell lysis buffer. Samples were lysed by using lysis buffer (CST) containing phosphatase inhibitor cocktail (Sigma, Poole, UK) and protease inhibitor cocktail (Roche Diagnostics, Burgess Hill, UK). Following quantification using Pierce BCA Protein Assay Kit (Thermo Fisher), equal amounts of cell extracts were loaded for Western blot analysis. Membranes were incubated with primary antibody (1:1000) overnight at 4 °C, and horseradish peroxidase secondary antibody (Amersham Bioscience, Amersham, UK) for 1 h at room temperature. Signal was detected with ECL Prime western blotting detection agent (Amersham Biosciences), visualised using Hyperfilm ECL (Amersham Biosciences) and analysed using an X-ray film processor in accordance with standard protocols. Primary antibodies used were phospho-
SMAD1/5/8 (CST#13820), phospho-AKT (Ser473, CST#4060), total AKT (CST#9272) and GAPDH (CST#2118), all Cell Signalling (Danvers, MA, USA), and SMAD1/5/8 (SC#6031), and ID1 (SC#488), both Santa Cruz Biotechnology (Dallas, TX, USA).

Tolerability and pharmacokinetics

NOD.SCID animals were treated with an oral dose (PO) of everolimus (5mg/kg) or vehicle (10% w/v hydroxypropylbetacyclodextrin in PBS) followed 30min later by an intraperitoneal (IP) dose of vandetanib (25mg/kg) or vehicle during 14 consecutive days. Plasma and brain tissue samples were taken in triplicate at 1h post-last dose. Analysis was carried out by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a Waters Xevo TQS coupled with an Acquity UPLC H-class system (Waters, Herts, UK). Chromatography was carried out using a Phenomenex (Macclesfield, UK) C18 X-B column (2.6µm, 50 mm × 2.1 mm). Data acquisition was performed using Targetlynx, version 4.1 and modelling was carried out using Phoenix WinNonlin version 6.3 (Certara, NJ, USA).

In vivo efficacy studies

Both patient-derived H3F3A K27M, ACVR1 R206H HSJD-DIPG-007 cells, and those derived from a Nestin-Tv-a, Trp53fl/fl, Hist1h3b K27M, Acvr1 R206H (14) genetically engineered mouse model (GEMM) were used for orthotopic implantation. A single cell suspension of each culture was made the day before implantation and cultured overnight. On the implantation day, small tumourspheres in exponential growth were harvested by mild centrifugation. 3-week-old female athymic mice were anaesthetised with 100 mg/kg ketamine and 10 mg/kg xylazine and immobilized in a stereotaxic apparatus (Stoelting, Wood Dale, IL) at coordinates x+0.5 and y−5.4 from the bregma suture. HSJD-DIPG-007 tumourspheres (5 × 10⁵ cells), suspended in 5 μl matrigel (BD Biosciences) were injected at 3.1 mm depth (targeting the 4th ventricle) with a dull 22G needle attached to a 50 μl syringe (Hamilton, Bonaduz, Switzerland), using a stereotaxic arm. The animals (n = 72) were divided in 4 groups with treatment starting four
weeks (day 25) after tumour inoculation. The treatment arms comprised: Group 1 – DMSO-saline vehicle, n=22; Group 2 – 25 mg/kg/day vandetanib (IP) daily for a 5-day period, for four consecutive weeks, n=16; Group 3 – 5 mg/kg/day everolimus (PO), daily for a 5-day period, for four consecutive weeks, n=17; Group 4 – 25 mg/kg/day vandetanib (IP) and 5 mg/kg/day everolimus (PO), both daily for 5 days on, 2 days off per week, for four consecutive weeks, n=17. Everolimus was dosed 30 min before vandetanib. Mice were monitored by daily weighing and were sacrificed by decapitation upon deterioration of condition or 20% weight loss from the maximum weight achieved, with tissue taken for further analysis. Mouse brains collected at the end of the efficacy study were processed for immunohistochemistry. Plasma and brain samples from treated and control mice were taken at 2 h post-dose at the end of the 4-week treatment for pharmacokinetic and pharmacodynamic analyses.

**Immunohistochemistry**

PFA-fixed mouse brains were paraffin embedded and sectioned (4 µm) for immunohistochemical analysis and stained with haematoxylin and eosin (H&E). For immunohistochemistry, sodium citrate (pH 6.0) heat-mediated antigen retrieval was performed and staining was carried out using an antibody directed against human nuclear antigen (HNA) (Millipore, #4383, 1:100). Pressure antigen retrieval was performed and staining was carried out using antibodies directed against Ki67 (DAKO, #7240, 1:100), and CD31 (Abcam, #28364, 1:50). All primary antibodies were diluted into 1% Tris buffer solution with 0.05% Tween-20, except Ki67 which was diluted into Dako antibody diluent. Antibodies were incubated for 1 h at room temperature. Novocastra Novolink Polymer Detection Systems Kit (Leica Biosystem RE-7150) was used for the staining. Slides were then mounted using Leica CV Ultra mounting medium and slides were imaged using the high throughput-scanning microscope AxioScan Z1 and quantified using Definiens software.

**Droplet-digital PCR (ddPCR)**
Droplet digital PCR was carried out on genomic DNA extracted from FFPE rolls from sagittal cuts of brains used for tumour burden study, using the QIAamp DNA FFPE Tissue Kit (Qiagen). Custom TaqMan-based quantitative PCR genotyping assays (Bio-Rad; Applied Biosystems) were designed to specifically detect the ACVR1 R206H mutation present in HSJD-DIPG-007 (Fwd Primer – GAATTACCGACACACTCACAAGT, Rev Primer – CTCTGGCTTTTCTCTGTACAA). The Bio-Rad QX200 ddPCR system was used. DNA was randomly encapsulated into approximately 15,000 oil nanoliter-sized droplets, using the Automated Droplet Generator (BioRad, QX200 AutoDG), containing ddPCR Supermix for probes (no dUTP) (BioRad, 1863024), genotyping assay (VIC, wild-type – AGTGGCTCGCCAGATT; FAM, mutant - CAGTGGCTCACCAGATT), water and the DNA of interest. The PCR reaction was performed in a thermocycler, plates were then placed on the droplet reader where the droplets are streamed individually through a detector and signals from mutant positive (FAM), wild-type (VIC), double-positive (FAM and VIC/HEX) and negative droplets (empty) are counted to provide absolute quantification of DNA in digital form. The mutant allele concentration (\(C_{\text{MUT}}\)) and wild-type allele concentration (\(C_{\text{WT}}\)) were calculated with Quantasoft Analysis Pro (BioRad) and the concentration of human DNA were calculated as previously described (57,58).

**Liquid biopsy extraction and sequencing**

Up to 10 ml of peripheral blood was collected into Cell-Free DNA Collection Tubes (Streck, La Vista, USA). Samples were centrifuged twice for 10min, first at 1,600g and at up to 16,000g to remove cellular contents and/or debris. cfDNA isolation from plasma was performed using the QIAamp circulating nucleic acid kit (Qiagen, 55114) following quantification using the Qubit fluorometer (ThermoFisher Scientific, dsDNA HS Assay kit, Q32854) and fragment analysis by 2200 and 4200 TapeStation (Agilent, Genomic DNA ScreenTape 5067-5366).

**Capillary-based protein quantification**
Capillary electrophoresis was conducted on protein lysates from the DIPG autopsy specimens using the automated Wes system (ProteinSimple) with the 12-230 kDa Separation module (SM-W004) and the anti-rabbit detection module (DM-001) following the manufacturer’s instructions and analyzed with Compass software. The following primary antibodies were used: ERK1/2 (1:100, Cell Signalling Technologies, 9102), phospho-ERK$^{T202/Y204}$ 1:100 (Cell Signalling Technologies, 9101), and α-Actin (1:200, Cell Signalling Technologies, 6487). Goat Anti-Rabbit HRP conjugate (Protein Simple, 042-206) was used as a secondary antibody.

Clinical treatment with vandetanib and mTOR-inhibitor

Four children with biopsy-confirmed ACVR1-mutant DIPG were treated with vandetanib and an mTOR-inhibitor in separate European institutions. All interventions were carried out with written informed consent from the patients’ families, were conducted in accordance with the Declaration of Helsinki, and under Ethical Review Board approval. The indication to use this combination and the clinical monitoring were at the discretion of the treating physician. Efficacy and safety data were collected retrospectively from each centre. Toxicity grading was performed as per CTCAE v4.03 for consistency with the BIOMEDE trial (NCT02233049).

Statistical analysis

Statistical analysis was carried out using R (www.r-project.org) and GraphPad Prism. Comparisons between groups of continuous variables employed Student’s t-test or ANOVA. Univariate differences in survival were analysed by the Kaplan-Meier method and significance determined by the log-rank test or median test. All tests were two-sided and a $p$ value of less than 0.05 was considered significant for simple comparisons. Bonferroni correction for multiple comparisons was applied for combinatorial experiments, with a $p$ value of less than 0.0083 considered significant.
REFERENCES


<table>
<thead>
<tr>
<th>Case</th>
<th>Age (yrs)</th>
<th>Gender</th>
<th>Histology</th>
<th>Mutations</th>
<th>RT (Gy / #)</th>
<th>Timing of combo</th>
<th>Cycles</th>
<th>Previous therapies</th>
<th>EFS months (Dx / combo)</th>
<th>OS months (Dx / combo)</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7</td>
<td>Female</td>
<td>DMG</td>
<td>HIST2H3C p.K27M ACVR1 p.G328V BCOR p.Met1020fs</td>
<td>54 / 30</td>
<td>Upfront</td>
<td>7</td>
<td>Everolimus</td>
<td>11 / 6.5</td>
<td>20 / 9</td>
<td>Dead</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>Female</td>
<td>DMG</td>
<td>HIST1H3B p.K27M ACVR1 p.G328E</td>
<td>54 / 30</td>
<td>Upfront</td>
<td>1</td>
<td>Bevacizumab</td>
<td>5 / 1</td>
<td>9 / 5</td>
<td>Dead</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>Female</td>
<td>DMG</td>
<td>HIST1H3B p.K27M ACVR1 p.G328E PIK3CA p.E542K</td>
<td>54 / 30</td>
<td>Relapse</td>
<td>1</td>
<td>re-RT, Bevacizumab, Sirolimus</td>
<td>8 / 0.7</td>
<td>16 / 0.7</td>
<td>Dead</td>
</tr>
</tbody>
</table>

*Cases #1 and #3 were treated with Vandetanib/Everolimus; case #2 was treated with Vandetanib/Sirolimus.DMG: diffuse midline glioma; Dx: diagnosis; EFS: event-free survival; Eve: everolimus; FU: follow up; Gy: grays; mTORi: mTOR inhibitor; OS: overall survival; re-RT: re-irradiation; RT: radiotherapy; Van: vandetanib; yrs: years; #: radiotherapy fractions.

Table 1 – Demographics of three children with newly diagnosed ACVR1-mutant diffuse intrinsic pontine glioma treated with vandetanib and mTOR-inhibitors upfront or at relapse.
Table 2 – Summary of toxicities graded as per CTCAE v4.03 related to vandetanib and/or mTOR-inhibitors in three children with newly diagnosed ACVR1-mutant diffuse intrinsic pontine glioma for a total of 9 cycles of vandetanib and 12 cycles of mTOR-inhibitor (11 cycles of everolimus and 1 cycle of sirolimus).
FIGURE LEGENDS

Figure 1 – Schema for artificial intelligence-based identification of a repurposed drug combination strategy for ACVR1-mutant DIPG. The BenevolentAI Knowledge Graph was employed to identify approved drugs with potential potency against ACVR1 and sufficient CNS penetration to be a rational therapy for children with DIPG. Vandetanib and everolimus were validated to inhibit ACVR1 and PgP, respectively, and the combination found to be synergistic in vitro and prolong survival in vivo, leading to the clinical use of this combination in three expert Paediatric Neuro-Oncology Centres in Europe.

Figure 2 – Validation of vandetanib as an ACVR1 inhibitor and everolimus as a PgP inhibitor. (A) Kinome selectivity map for vandetanib at 10µM, with red circles reflecting kinases inhibited by >65%. ACVR1 is labelled. The diameter of the circles is inversely proportional to the percentage kinase activity remaining in the presence of inhibitor. Taken from the Harvard Medical LINCS KINOMEscan database (lincs.hms.harvard.edu). (B) Barplots showing the IC50 for various compounds against wild-type (grey) and mutant (purple) ACVR1: Q207E, R206H and G328V. (C) Western blot of ACVR1_R206H HSJD-DIPG-007 cells treated with increasing concentrations of vandetanib in the presence of 0.1µM, 1.0µM or 10µM everolimus. GAPDH is the loading control. (D) Barplots showing apparent permeability (Papp) of a BCRP substrate across a bidirectional cell monolayer (A→B and B→A) in the presence of various inhibitors. (E) Barplots showing apparent permeability (Papp) of a PgP substrate across a bidirectional cell monolayer (A→B and B→A) in the presence of various inhibitors. Vandetanib, pink; everolimus, light orange; combination, dark red. Error bars represent standard deviation of the mean. *** p<0.0001, ANOVA. (F) Dot plot of vandetanib concentration in the brains of normal mice treated with vehicle control (grey), vandetanib (pink), or the combination (dark red), as assessed by mass spectrometry. The black horizontal line represents the median.
**Figure 3** – *Synergy of combined vandetanib and everolimus in vitro.* (A) Cell viability matrices for ACVR1_R206H HSJD-DIPG-007 cells treated with distinct combinations of vandetanib (y axes) and everolimus (x axes) ranging from 0-20µM. (B) Excess above BLISS matrices for ACVR1_R206H HSJD-DIPG-007 cells treated with distinct combinations of dasatinib (y axes) and trametinib (x axes) ranging from 0-20µM. (C) BLISS synergy maps for ACVR1_R206H HSJD-DIPG-007 cells treated with distinct combinations of dasatinib (y axes) and trametinib (x axes) ranging from 0-10µM. Heatmaps coloured according to the keys provided. (D) Cell viability matrices for ACVR1_R258G HSJD-DIPG-018 cells treated with distinct combinations of vandetanib (y axes) and everolimus (x axes) ranging from 0-20µM. (E) Excess above BLISS matrices for ACVR1_R258G HSJD-DIPG-018 cells treated with distinct combinations of vandetanib (y axes) and everolimus (x axes) ranging from 0-20µM. (F) BLISS synergy maps for ACVR1_R258G HSJD-DIPG-018 cells treated with distinct combinations of vandetanib (y axes) and everolimus (x axes) ranging from 0-10µM. Heatmaps coloured according to the keys provided.

**Figure 4** - *Efficacy of combined vandetanib and everolimus in vivo.* (A) Tolerability in NOD.SCID mice exposed to daily oral treatment with the combination of vandetanib and everolimus over 14 days, as assessed by body weight relative to day 0. Mean and standard deviation of 3 mice per group are plotted. (B) Schema for *in vivo* efficacy (survival) and tumour burden experiments in orthotopic PDX and GEMM allografts of mutant ACVR1-driven DIPG. (C) Survival curves for mice (n=16-22 per group) bearing HSJD-DIPG-007 orthotopic xenografts, treated with vandetanib (pink), everolimus (light orange), or the combination (dark red), compared with vehicle-treated controls (grey). (D) Barplot quantifying tumour burden as assessed by ddPCR for ACVR1_R206H in mice treated with vandetanib (pink), everolimus (light orange), or the combination (dark red), expressed as a percentage of vehicle-treated.
controls (grey). (E) Barplot quantifying cellularity by HNA-positive cells in mice treated with vandetanib (pink), everolimus (light orange), or the combination (dark red), expressed as a percentage of vehicle control (grey). Mean and standard deviation plotted. * p<0.05, adjusted t-test. (F) Survival curves for mice (n=16-22 per group) bearing Nestin-Tv-a; Trp53<sup>fl/fl</sup>; Hist1h3b_K27M, Acrv1_R206H orthotopic allografts, treated with vandetanib (pink), everolimus (light orange), or the combination (dark red), compared with vehicle-treated controls (grey). (G) Dot plot of vandetanib concentration in the normal brains and engrafted tumours of Nude mice treated with combined vandetanib and everolimus, as assessed by mass spectrometry. The black horizontal line represents the median. (H) Dot plot of vandetanib concentration in the normal brains and engrafted tumours of NSG mice treated with combined vandetanib and everolimus, as assessed by mass spectrometry. The black horizontal line represents the median.

**Figure 5** – Clinical experience of combined vandetanib and everolimus in a seven year-old girl with ACVR1-mutant DIPG (Case #1). (A) Timeline summarising the clinical history of Case#1, treated at the Royal Marsden Hospital, London, UK. * represent imaging scans presented below. (B) Sequential head MRI scans: diagnostic MRI showing diffuse heterogenous tumour infiltration and anatomical distortion of the pons including partial invagination of the basilar artery (i) with a single focus of intratumoural enhancement in the right central pons (ii); MRI scan 6 weeks after radiotherapy showed considerable reduction in tumour infiltrative bulk (iii) with the small focus of enhancement persisting in the right pons (iv); the MRI scan after 3 cycles of everolimus single agent constituted also the baseline scan prior to starting vandetanib/everolimus, it showed increased T2 signal abnormality in the right pons (v) associated with mildly increased focal enhancement (vi); the MRI scans after 3 cycles (vii, viii) and 6 cycles (ix, x) of vandetanib/everolimus showed modest enlargement and progressive infiltration of the right pons (vii, ix) with concomitant increase of the associated focal enhancement (viii, x), but nevertheless with relatively stable appearances/lack of...
progression elsewhere. The child started cycle 7 of vandetanib/everolimus, but then
developed worsening symptoms (slurred speech, ataxia) and treatment was permanently
discontinued 11 months after initial diagnosis. No further systemic treatment or re-irradiation
were administered. Steroids could be weaned off completely and her balance and activity
levels improved significantly. Eight months after discontinuation of vandetanib/everolimus she
developed further clinical and radiological progression (local and metastatic) and passed away
a month later (overall survival 20 months). (C) Macroscopic transverse cross-section of pons
and cerebellum from the brain autopsy specimen from Case#1. (D) Haematoxylin and eosin
stained image from the inferior left pons (x40), with a higher magnification inset (x200) of
region 1, showing diffuse infiltration of tumour cells. (E) Protein structure representation of
KRAS showing mutant G12A residue (shaded red), generated in COSMIC-3D
(cancer.sanger.ac.uk/cosmic3d). Allelic fractions are provided for mutant reads identified in
distinct areas of the pons taken at autopsy. (F) MAPK pathway activation in distinct autopsy
regions measured by quantitative capillary electrophoresis for phospho-ERK1/2T202/Y204,
plotted as a ratio of respective phosphorylated/total protein compared to normal cerebellum.
ACKNOWLEDGEMENTS

We acknowledge the patients and families who participated in this work. This study was supported by Brain Research UK, the DIPG Collaborative, Children with Cancer UK, Abbie’s Army, Lucas’ Legacy, the Lyla Nsouli Foundation and Cancer Research UK. The authors acknowledge NHS funding to the National Institute for Health Research Biomedical Research Centre at The Royal Marsden and the ICR. FC is partly funded by The Giant Pledge via the Royal Marsden Cancer Charity. We acknowledge Dr Vivek Subbiah, MD Anderson Cancer Centre, for his clinical advice and expert guidance. We thank Louise Howell (ICR) for excellent technical assistance. Vandetanib was kindly provided by Sanofi Genzyme, and everolimus by Novartis UK, under their Managed Access Programmes in response to an unsolicited request from the treating clinicians.
Figure 1

**Discovery**
- ACVR1 inhibition
- CNS penetration
- Tested in humans
- Benevolent AI Knowledge Graph
  - ACVR1-mutant DIPG
- Vandetanib
- Everolimus
- Combination

**Validation**
- Inhibits ACVR1
- Inhibits PgP
- Synergy *in vitro*
- Efficacy *in vivo*

**Clinical experience**
- Dosing, safety, ctDNA
  - Royal Marsden Hospital, London UK
  - Hospital Sant Joan de Deu, Barcelona ES
  - DIPG Centre of Expertise, Zurich CH
  - Institut Gustave Roussy, Paris FR

[Diagram Image]
Figure 3

HSJD-DIPG-007 H3F3A K27M, ACVR1 R206H

A

Everolimus (μM)

B

Everolimus (μM)

C

Bliss synergy score = 17.249

D

Everolimus (μM)

E

Everolimus (μM)

F

Bliss synergy score = 4.082

HSJD-DIPG-018 HISTH3B K27M, ACVR1 R258G

Cell viability

Excess above BLISS

Cell viability

Excess above BLISS

Downloaded from cancerdiscovery.aacrjournals.org on November 14, 2021.
**Figure 4**

**A**

Body weight as % of day 0

**B**

4 weeks treatment
5 days on / 2 days off

**C**

HS JD-DIPG-007 H3F3A K27M, ACVR1 R206H (nude)

**D**

Vehicle
Vandetanib
Everolimus
Combination

\[ p = 0.0034 \]

**E**

\[ \% \text{Control (total DNA)} \]

**F**

Nestin-Tv-a; Trp53<sup>fl/fl</sup>; Histh3b K27M, Acvr1 R206H (NSG)

**G**

\[ \% \text{Control (DNA positive cells)} \]

**H**

NSG

Concentration (μM)
Figure 5

A

<table>
<thead>
<tr>
<th>Dr.</th>
<th>Biopsy</th>
<th>Radiotherapy</th>
<th>Everolimus</th>
<th>Progression 1</th>
<th>Progression 2</th>
<th>Died of Disease</th>
<th>Case #1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.2w</td>
<td>10w</td>
<td>18w</td>
<td></td>
<td></td>
<td></td>
<td>7 year old female</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HIST2H3C_K27M, ACVR1_G328V</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19m20m</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

Diagnosis | Post-RT | Pre-cycle 1 | Pre-cycle 4 | Pre-cycle 7

Axial T2-weighted

Axial T1 post-contrast

C

D

Inferior left pons

E

KRAS_G12A

Pons

Biopsy

<table>
<thead>
<tr>
<th></th>
<th>L1</th>
<th>L2</th>
<th>R1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>23389</td>
<td>2310</td>
<td>4210</td>
</tr>
<tr>
<td>(0.02)</td>
<td>(0.05)</td>
<td>(0.02)</td>
<td></td>
</tr>
</tbody>
</table>

Reads (allelic fractions)

F

pERK1/2

Phosphorylation relative to cerebellum

<table>
<thead>
<tr>
<th></th>
<th>L3</th>
<th>L4</th>
<th>R2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3.5</td>
<td>3.0</td>
<td>2.5</td>
</tr>
</tbody>
</table>

Cerebellum

Pons
Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma

Diana M Carvalho, Peter J Richardson, Nagore Olaciregui, et al.

Cancer Discov  Published OnlineFirst September 22, 2021.

Updated version
Access the most recent version of this article at: doi:10.1158/2159-8290.CD-20-1201

Supplementary Material
Access the most recent supplemental material at: http://cancerdiscovery.aacrjournals.org/content/suppl/2021/09/21/2159-8290.CD-20-1201.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/early/2021/09/20/2159-8290.CD-20-1201. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.